Samsara BioCapital’s Terns Pharmaceuticals TERN Stock Holding History

Samsara BioCapital’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-135,573	Closed	-$1.02M	–	28
2025 Q3	$1.02M	Sell	135,573 -66,775	-33%	-$426K	0.13%	24
2025 Q2	$755K	Hold	202,348	–	–	0.15%	25
2025 Q1	$558K	Hold	202,348	–	–	0.1%	30
2024 Q4	$1.12M	Hold	202,348	–	–	0.15%	33
2024 Q3	$1.69M	Hold	202,348	–	–	0.32%	30
2024 Q2	$1.38M	Hold	202,348	–	–	0.29%	30
2024 Q1	$1.33M	Hold	202,348	–	–	0.21%	32
2023 Q4	$1.31M	Hold	202,348	–	–	0.2%	30
2023 Q3	$1.02M	Hold	202,348	–	–	0.31%	32
2023 Q2	$1.77M	Hold	202,348	–	–	0.31%	32
2023 Q1	$2.4M	Hold	202,348	–	–	0.5%	31
2022 Q4	$2.06M	Sell	202,348 -86,720	-30%	-$577K	0.44%	32
2022 Q3	$1.7M	Hold	289,068	–	–	0.4%	37
2022 Q2	$717K	Hold	289,068	–	–	0.19%	46
2022 Q1	$859K	Hold	289,068	–	–	0.22%	48
2021 Q4	$2.04M	Hold	289,068	–	–	0.4%	36
2021 Q3	$3.01M	Hold	289,068	–	–	0.47%	34
2021 Q2	$3.54M	Sell	289,068 -208,487	-42%	-$3.55M	0.44%	33
2021 Q1	$10.9M	Buy	+497,555	New	+$10.9M	2.02%	14

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CLGM

Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

Samsara BioCapital's TERN Position: Q4 2025 in Review

Samsara BioCapital sold out of Terns Pharmaceuticals (TERN) in Q4 2025, closing a stake of 135,573 shares — an estimated $1.02M sold.

Samsara BioCapital first reported a position in TERN in Q1 2021 and held it in 19 quarters. The position peaked at $10.9M in Q1 2021. 248 funds tracked by Wall St. Rank hold TERN as of Q4 2025.

Samsara BioCapital reported no remaining Terns Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Samsara BioCapital sold 135,573 Terns Pharmaceuticals shares in Q4 2025, an estimated $1.02M.
Samsara BioCapital first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 19 quarters.
Samsara BioCapital's Terns Pharmaceuticals position peaked at $10.9M in Q1 2021.
248 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2025.

Based on Samsara BioCapital's 13F filing for Q4 2025, filed 17 Feb 2026.